缺氧诱导因子-1α及血管生长因子与晚期卵巢浆液性癌腹膜播散和预后相关性分析  

Role of Hypoxia-inducible Factor-1α(HIF-1α) and Angiogenic Factors in Peritoneal Metastases and Prognosis of Advanced Serous Ovarian Cancer

作　　者：佟晓光[1] 徐惠绵[2] 刘云鹏[3] 侯科佐[3] 

机构地区：[1]中国医科大学附属第一医院妇科,沈阳市110001 [2]中国医科大学附属第一医院肿瘤外科,沈阳市110001 [3]中国医科大学附属第一医院肿瘤内科,沈阳市110001

出　　处：《中国肿瘤临床》2008年第5期272-276,共5页Chinese Journal of Clinical Oncology

基　　金：国家自然科学基金资助(编号:30672050)

摘　　要：目的:探讨HIF-1α、VEGF、bFGF及MVD在晚期卵巢浆液性癌腹水形成和腹膜播散中的作用,及其与预后的关系。方法:采用免疫组织化学方法检测HIF-1α、VEGF、bFGF、CD34蛋白在31例人晚期卵巢浆液性癌原发灶、腹水沉渣和腹腔转移灶中的表达,分析上述四种因子与预后的关系。结果:HIF-1α、VEGF蛋白在31例晚期卵巢浆液性囊腺癌原发灶、转移灶中的表达高于腹水中的表达(P<0.05),bFGF在31例晚期卵巢浆液性囊腺癌原发灶、转移灶和腹水中均高表达,无显著性差异(P>0.05)。残留病灶大小、HIF-1α、VEGF、bFGF及MVD表达与晚期卵巢浆液性囊腺癌的复发或转移具有明显的正相关(P<0.05)。Cox模型分析,VEGF及MVD是晚期卵巢浆液性囊腺癌的独立预后因素(P<0.05)。结论:HIF-1α、VEGF和bFGF在卵巢浆液性囊腺癌腹水形成和腹膜转移中有重要的作用,VEGF及MVD是晚期卵巢浆液性囊腺癌的独立预后因素。Objective： To evaluate the role of hypoxia-inducible factor-1α （HIF-1α） and angiogenic tactors in peritoneal metastases and prognosis of advanced serous ovarian cancer. Methods： Sections of effusions and primary and metastatic lesions from 31 ovarian serous carcinoma patients were evaluated for the expression of hypoxia-inducible factor-let（HIF-1α）, basie-broblast faetor（bFGF）, and vascular endothelial growth factor（VEGF） hy immunohistochemistry （IHC）. Results： HIF-1α and VEGF expression showed a remarkable downregulation in the efiusions, compared with those in the primary and metastatic sites （P〈0.05）. In contrast, constantly high expression of bFGF was observed in all of the three kinds of samples. The size of the residual mass, the expression of HIF-1α, VEGF, bFGF and MVD in tumor cells were correlated with cancer recurrence （P〈0.05）. In a multivariate Cox regression model. VEGF and MVD were independent prognostic, factors （P〈0.05）. Conclusion： HIF-1α, VEGF and bFGF play important roles in peritoneal metastasis of serous ovarian caneer. VEGF and MVD were independent prognostic factors for patients with advanced serous ovarian cancer.

关 键 词：缺氧诱导因子-1Α 血管内皮生长因子 碱性成纤维细胞生长因子 卵巢浆液性囊腺癌 

分 类 号：R737.31[医药卫生—肿瘤] R730.2[医药卫生—临床医学]